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Abstract
Background: Cardiovascular diseases (CVD) are the main cause of death and disability in developed countries. In
most cases, the progress of CVD is influenced by environmental factors and multifactorial inheritance. The purpose
of this study was to investigate the association between APOE genotypes, cardiovascular risk factors, and a non-
invasive measure of arterial stiffness in the Brazilian population.
Methods: A total of 1493 urban Brazilian individuals were randomly selected from the general population of the
Vitoria City Metropolitan area. Genetic analysis of the APOE polymorphism was conducted by PCR-RFLP and pulse
wave velocity analyzed with a noninvasive automatic device.
Results: Age, gender, body mass index, triglycerides, creatinine, uric acid, blood glucose, blood pressure
phenotypes were no different between ε2, ε3 and ε4 alleles. The ε4 allele was associated with higher total-
cholesterol (p < 0.001), LDL-C (p < 0.001), total-cholesterol/HDL-C ratio (p < 0.001), LDL/HDL-C ratio (p < 0.001),
lower HDL-C values (p < 0.001) and higher risk to obesity (OR = 1.358, 95% CI = 1.019-1.811) and hyperuricemia
(OR = 1.748, 95% CI = 1.170-2.611). Nevertheless, pulse wave velocity (p = 0.66) measures were no different
between genotypes. The significant association between APOE genotypes and lipid levels persisted after a 5-year
follow-up interval, but no interaction between time and genotype was observed for lipids longitudinal behavior.
Conclusion: The ε4 allele of the APOE gene is associated with a worse lipid profile in the Brazilian urban
population. In our relatively young sample, the observed effect of APOE genotype on lipid levels was not translated
into significant effects in arterial wall stiffness.
Background
Cardiovascular diseases (CVD) are the main cause of
death and disability in developed countries. In most
cases, the progress of CVD is influenced by multifactor-
ial inheritance and environmental factors [1-4]. Lipopro-
tein disorders such as elevated low-density lipoprotein
cholesterol (LDL-C ≥ 160 mg/dL), low high-density lipo-
protein cholesterol (HDL-C < 40 mg/dL) and elevated
concentration of triglycerides (TG ≥ 150 mg/dL) are
considered significant risk factors in the pathogenesis of
CVD [5].
Apolipoprotein E (ApoE) is a glycoprotein that plays a
fundamental role in the lipid metabolism. ApoE partici-
pates in the clearance of chylomicron remmants and
very low-density lipoprotein (VLDL) by serving as a
ligand for LDL receptors [6].I ti sa l s oi m p o r t a n tf o r
intestinal cholesterol absorption [7] and plasma lipid
maintenance [8]. The APOE gene, located on chromo-
some 19 [9], is composed by three alleles (ε2, ε3 and ε4)
that give rise to six different genotypes (ε2/2, ε2/3, ε2/4,
ε3/3, ε3/4, and ε4/4) [6]. The ε3 allele differs from the
ε2 allele by an amino acid substitution of arginine for
cysteine at codon 158, while the ε4 differs from ε3b ya
substitution of arginine for cysteine at residue 112
[10-12]. Many studies assessing the role of APOE poly-
morphism on plasma lipids have shown that the
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any medium, provided the original work is properly cited.presence of the ε4 allele is associated with elevations in
LDL-C, while the presence of ε2 is associated with
decreased levels of LDL-C [13]. Moreover, some studies
have reported that the ε4 allele is associated with coron-
ary heart disease [14] although most of these have been
carried out in male subjects.
After the discovery of the APOE gene and knowledge
of its genetic variants, several studies have demonstrated
the association between the APOE polymorphisms and
chronic conditions, such as Alzheimer’s disease [15],
age-related cognitive decline [16], osteoporosis [17],
breast cancer [18], end-stage renal disease [19], athero-
sclerosis [8], diabetes [20], coronary disease [21] and
longevity [22]. Based on these, we aimed to assess the
relation between APOE genotype groups with the preva-
lence of the major CVD risk factors and its possible
association with the evolution of the studied phenotypes
in a longitudinal study of Brazilian subjects randomly
selected from an ethnically mixed urban population.
Our hypothesis was that individuals carrying the ε4
allele had a worse lipid profile when compared with ε2
and ε3 alleles carriers of the APOE polymorphism and
that this worse profile would be translated into signifi-
cantly different measures of arterial stiffness.
Methods
Study Design and Participants
A cross-sectional study of risk factors for cardiovascular
diseases was performed in the urban population of the
Vitória city, Brazil, using the WHO-MONICA project
guidelines [23]. In the first stage of the study, conducted
in 1999, 1493 Brazilians of either gender, aged 25 to 64
years were chosen according to the nearest birthday
[24]. All participants were submitted to complete clini-
cal and laboratorial investigations for CVD risk factors.
This study was approved by the Ethics Committee for
Research on Human Subject of the Espírito Santo Fed-
eral University, and all subjects gave written informed
consent to participate.
Risk Factors Assessment
Anthropometrical Investigations
Weight and height were measured according to a stan-
dard protocol, with participants wearing light clothing
and no shoes. Height was measured in centimeters and
weight in kilograms using a calibrated balance. Body
mass index (BMI) was calculated and obesity defined as
BMI ≥ 30Kg/m
2 [25]. Individuals who had ever smoked
more than five cigarettes per day for the last year were
classified as smokers [26]. Participants were also sub-
mitted to an ethnic classification according to a vali-
dated questionnaire for the Brazilian population [27].
Subjects were classified as Caucasian or Afro-descendent
according to a set of phenotypic characteristics (skin
color, hair texture, shape of the nose and aspect of the
lip). On the basis of these characteristics, mulattos are
considered racially mixed subjects.
Blood Pressure Phenotype Determination
Blood pressure was measured in the sitting position with
the use of a standard mercury sphygmomanometer on
the left arm after 5 minutes’ rest. The first and fifth
phases of Korotkoff sounds were used for systolic (SBP)
and diastolic pressure (DBP), respectively. The SBP and
DBP were calculated from two readings with a minimal
interval of 10 minutes. Hypertension was defined as
mean SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg or
use of anti-hypertension drugs [28]. Pulse pressure (PP)
was the difference between SBP and DBP. The mean
blood pressure (MBP) was calculated as the mean pulse
pressure added to one-third of the DBP.
Pulse wave measurements
The Carotid-femoral pulse wave velocity (PWV) was
analyzed with a noninvasive automatic device (Complior;
Colson; Garges les Gonesses, France) by an experienced
observer blinded to the clinical characteristics. Briefly,
common carotid artery and femoral artery pressure
waveforms were recorded noninvasively using a pres-
sure- sensitive transducer (TY-306-Fukuda; Fukuda;
Tokyo, Japan). The distance between the recording sites
(D) was measured, and PWV was automatically calcu-
lated as PWV = D/t, where (t) means pulse transit time.
Thirty measurements were repeated over 10 different
cardiac cycles, and the mean is used for the final analy-
sis. Because systolic BP has direct influence on PWV,
we also adjusted PWV for the mean systolic BP in all
groups. The validation of this automatic method and its
reproducibility has been previously described [29].
Biochemical Measurement
Blood glucose, TG, lipoprotein fractions and uric acid
were assayed by standard techniques in 12-h fasting
blood samples [30].This study, diabetes was defined as
fasting glucose ≥ 126 mg/dL or use of hypoglycemic
drugs. Abnormal biochemical levels were identified
when total-cholesterol (TC) ≥ 200 mg/dL, TG ≥ 150
mg/dL, LDL-C ≥ 160 mg/dL, HDL-C < 40 mg/dL and
uric acid ≥ 7.0 mg/dL [5,31].
DNA Extraction and APOE genotyping
Genomic DNA was extracted from leukocytes in sam-
ples of whole blood, following a standard salting-out
technique [32]. Genotypes were detected by polymerase
chain reaction followed by restriction fragment length
polymorphism analysis as previously described [33]. In
addition, we have genotyped samples for the APOE
polymorphisms (rs7412 and rs429358) by an additional
method (HRM analysis - high resolution melting).
Briefly, PCR with a fluorescent DNA-intercalating
SYTO9® (Invitrogen, Carlsbad, USA) was performed
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AGAAG-3’ and 5’-CACGCGGCCCTGTTCCAC-3’
(fragment size 117 pairs base) and 5’-GCGGACAT-
GGAGGACGTG-3’ and 5’- AGCTCCTCGGTGCT-
CTGG-3’ (fragment size 83 pairs base), for rs7412 and
rs429358, respectively. In the HRM phase, Rotor Gene
6000® (Qiagen, Courtaboeuf, France) measured the
fluorescence in each 0.1°C temperature increase in the
range of 70-94°C. Melting curves were generated by
the decrease in fluorescence with the increase in the
temperature; nucleotide changes resulting from different
curve patterns were analyzed and genotyped (Figure 1).
Samples of the three observed curves were sequenced
(ABI 3500XL Sequencer®, Applied Biosystems, Foster
City, CA, USA) to confirm the genotypes indicated by
HRM.
Quality control for the APOE polymorphisms (rs7412
and rs429358) was assessed by randomly selecting 96
samples to be re-genotyped using a high resolution
melting method (HRM analysis, Rotor Gene 6000®,
Qiagen, Courtaboeuf, France) by two independent tech-
nicians and these results were 100% concordant.
Statistical Analysis
To evaluate the effect of APOE genotypes on cardiovas-
cular risk factors, subjects were categorized into three
groups: ε2 carriers (ε2/ε2+ε2/ε3 genotypes), ε3 carriers
(ε3/ε3 genotype) and ε4 carriers (ε4/ε4+ε3/ε4g e n o -
types) [34]. In each model, the homozygous ε3/ε3 geno-
types formed the reference group. Thirty-two
individuals (2.3%) with ε2/ε4 genotype were excluded
from the analysis because of the putative opposite
effects of these two alleles on LDL-C levels [35].
Differences in the baseline cardiovascular risk charac-
t e r i s t i c sa c r o s st h eAPOE groups were tested by One-
Way ANOVA for continuous variables, and c
2 test for
categorical parameters. Table 1 shows the comparison
of data among all allelic groups. All variables were
adjusted for ethnicity, age and gender, except the PWV
was adjusted for age, SBP and ethnicity.
Logistic regression analysis was carried out to estimate
the odds ratio (OR), with 95% confidence intervals (CI),
in order to assess genetic risk factors for common cardi-
ovascular risk. The risk analysis was performed compar-
ing all three groups together. In the Table 2, we present
risk estimative for E2 and E4 allele carriers against all
other allele groups.
Quantitative variables were expressed as the mean ±
standard deviation, while qualitative variables were
expressed as percentage. Hardy-Weinberg equilibrium
for the distribution of the genotype groups was esti-
mated using the Haploview software. All statistical ana-
lyses were carried out using SPSS software (v. 16.0),
with the level of significance set at p < 0.05.
Results
The frequency of APOE genotypes among 1461 partici-
pants were: ε2/ε2 - 0.4%, ε2/ε3 - 9.7%, ε2/ε4 - 2.3%, ε3/
ε3-6 1 . 0 % ,ε3/ε4-2 4 . 4 %a n dε4/ε4 - 2.2%. The allele
frequencies were: ε2-1 0 . 1 % ,ε3 - 61.0% and ε4 - 26.6%.
The genotype distributions for APOE polymorphisms
(rs7412 and rs429358) were in Hardy-Weinberg equili-
brium (p > 0.05). The ethnicity proportion was different
among the APOE allele groups (p = 0.002), where the
number of Caucasians is higher than Afro-descendent in
the ε3 allele group (67.0% vs. 51.6%, respectively). Com-
parative analysis failed to indicate a significant difference
among APOE groups and age (p = 0.28), gender (p =
0.13), diabetes (p = 0.81) and smoking status (p = 0.66)
(Table 1).
Figure 1 Genotyping of rs7412 through HRM analysis. A: Normalized fluorescence by temperature. B: Normalized fluorescence (based on
genotype 1) by temperature. 1: wild-type genotype; 2: heterozygous genotype; 3: homozygous genotype for the APOE rs7412 polymorphism.
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Hemodynamic phenotypes of SBP (p = 0.15), DBP (p =
0.34), MBP (p = 0.21), PP (p = 0.34) and PWV (p =
0.66) showed no association with APOE allele groups
(Table 1). Similarly, risk analysis performed by multiple
logistic regression failed to detect significant genetic risk
for high SBP (ε2c a r r i e r s :O R=0 . 7 8 6 ,9 5 %C I=0 . 5 2 6 -
1.173, ε4 carriers: OR = 1.140, 95% CI = 0.858-1.515)
and high DBP (ε2 carriers: OR = 1.096, 95% CI = 0.776-
1.549) and ε4 carriers: OR = 0.968, 95% CI = 0.745-
1.257) (Table 2).
Table 1 Baseline characteristics of participants encoding ε2, ε3 and ε4 alleles of the APOE polymorphism
Subject Characteristics n, (%) ε2 180 (12.3%) ε3 893 (61.1%) ε4 388 (26.6%) p value
Gender, male 76 (42.2%) 433 (48.5%) 169 (43.6%) 0.13
Ethnicity
African descendent 19 (15.6%) 63 (51.6%) 40 (32.8%)
Caucasian descendent 50 (9.1%) 367 (67.0%) 131 (23.9%) 0.002
Mulatto 111 (14.1%) 463 (58.5%) 217 (27.4%)
Smoking status, smokers (%) 43 (23.9%) 211 (23.6%) 101 (26.0%) 0.66
Diabetes (%) 13 (7.2%) 70 (7.8%) 34 (8.7%) 0.81
Age, years 43.8 ± 10.6 45.1 ± 10.9 44.5 ± 10.8 0.28
BMI, kg/m2 25.8 ± 4.7 26.3 ± 4.9 26.4 ± 4.9 0.27
SBP, mmHg 125.9 ± 19.7 128.1 ± 21.5 129.4 ± 22.6 0.15
DBP, mmHg 83.3 ± 13.9 84.5 ± 14.1 85.1 ± 14.1 0.34
PP, mmHg 42.6 ± 11.4 43.7 ± 13.7 44.3 ± 14.3 0.34
MBP, mmHg 97.5 ± 15.2 99.0 ± 15.8 99.8 ± 16.1 0.21
PWV, m/s 10.0 ± 2.1 9.8 ± 2.2 9.8 ± 2.1 0.66
Triglycerides, mg/dL 133.7 ± 99.1 133.9 ± 124.4 145.9 ± 148.6 0.28
Total cholesterol, mg/dL 201.4 ± 50.6 215.2 ± 48.3* 218.6 ± 44.6† < 0.001
HDL - C, mg/dL 48.8 ± 14.6 45.5 ± 12.7* 43.2 ± 10.1†‡ < 0.001
LDL - C, mg/dL 125.3 ± 35.8 143.6 ± 38.9* 147.9 ± 39.6† < 0.001
VLDL - C, mg/dL 25.3 ± 17.2 25.5 ± 22.9 26.2 ± 15.5 0.81
Total cholesterol/HDL - C ratio 4.3 ± 1.4 5.0 ± 1.5* 5.3 ± 1.5† < 0.001
LDL - C/HDL - C ratio 2.8 ± 1.0 3.4 ± 1.2* 3.6 ± 1.3†‡ < 0.001
Glucose, mg/dL 103.9 ± 30.1 105.8 ± 33.0 104.4 ± 31.0 0.64
Creatinine, mg/dL 0.99 ± 0.19 0.97 ± 0.20 0.96 ± 0.20 0.16
Uric acid, mg/dL 4.7 ± 1.4 4.8 ± 1.5 5.0 ± 1.6† 0.04
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pressure pulse; MBP, mean blood pressure; PWV, pulse wave velocity; HDL -
C, high-density lipoprotein cholesterol; LDL - C, low-density lipoprotein cholesterol; VLDL - C, very-low-density lipoprotein cholesterol.
ε2 allele = ε2/ε2+ε2/ε3 genotypes; ε3 allele = ε3/ε3 genotype; ε4 allele = ε3/ε4+ε4/ε4 genotypes.
* ε2v sε3, p < 0.05; † ε2v sε4, p < 0.05; ‡ ε3v sε4, p < 0.05.
All values were adjusted for ethnicity, age and gender except the PWV was adjusted for age, SBP and ethnicity.
Table 2 Analysis of the cardiovascular risk factors associated with APOE polymorphism
APOE ALLELES
ε2 ε4
VARIABLES OR CI 95% p value OR CI 95% p value
Total cholesterol 0.44 0.319 - 0.618 < 0.001 1.571 1.218 - 2.026 0.001
HDL - C 0.584 0.400 - 0.854 0.005 1.271 0.982 - 1.644 0.07
LDL - C 0.401 0.262 - 0.614 < 0.001 1.738 1.343 - 2.250 < 0.001
Uric Acid 0.500 0.237 - 1.056 0.07 1.748 1.170 - 2.611 0.006
SBP 0.786 0.526 -1.173 0.13 1.140 0.858 - 1.515 0.37
DBP 1.096 0.776 - 1.549 0.60 0.968 0.745 - 1.257 0.81
BMI 0.717 0.466 - 1.104 0.13 1.358 1.019 - 1.811 0.04
Adjusted values for ethnicity, gender and age.
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Biochemical measurement of TC, LDL-C, HDL-C, TC/
HDL ratio and LDL-C/HDL and uric acid were asso-
ciated with the APOE polymorphism, even after adjust-
ment for ethnicity, age and gender. Values of TC (p <
0.001), LDL-C (p < 0.001), TC/HDL ratio (p < 0.001)
and LDL/HDL-C ratio were higher in ε4a n dε3w h e n
compared to ε2 allele carriers. However, for TC, LDL-C
and TC/HDL-C no difference was observed between ε2
and ε3 alleles (p > 0.05). The HDL-C values (p < 0.001)
were lower in ε4a n dε3 alleles when compared with ε2
allele carriers. In addition, ε3 carriers showed higher
HDL-C values when compared with ε4 allele carriers.
The uric acid values (p = 0.04) were lower in ε2a l l e l e
when compared with ε4 allele carriers. Other variables,
such as TG (p = 0.28), VLDL-C (p = 0.81), glucose (p =
0.64), creatinine (p = 0.16) and BMI (p = 0.27) failed to
show association with APOE groups (Table 1).
The ε2 allele confers protection for high TC (OR =
0.444, 95% CI = 0.319-0.618), low HDL-C (OR = 0.584,
95% CI = 0.400-0.854), high LDL-C (OR = 0.401, 95%
CI = 0.262-0.614), while ε4 allele confers risk for ele-
vated levels of TC (OR = 1.571, 95% CI = 1.218-2.026),
LDL-C (OR = 1.738, 95% CI = 1.343-2.250), uric acid
(OR = 1.748, 95% CI = 1.170-2.611) and BMI (OR =
1.358, 95% CI = 1.019-1.811) (Table 2).
Discussion
T h em a i nf i n d i n go ft h ep r e s e n ts t u d yw a st h a tAPOE
genetic variability is associated with cardiovascular risk
factors in a Brazilian urban population. Increased LDL-
C, TC, TC/HDL-C ratio, LDL-C/HDL-C ratio and
decreased HDL-C values were observed in individuals
harboring the ε4 allele. However, this genetic variant
was not associated with the arterial stiffness phenotype.
Corroborating our results, Medina-Urrutia et al [13]
demonstrated associations between the ε4 allele of the
APOE polymorphism and higher concentrations of TC,
LDL-C and lower HDL-C levels when compared with
the ε2 allele carriers in Mexican adolescents. Similarly,
Shu Liang et al [36] studying 168 healthy Chinese indi-
viduals showed associations between the ε4 allele with
increased TC and LDL-C values. However, HDL-C was
not associated with the genetic variant studied. In the
Brazilian population, de-Andrade et al [37] studying
individuals of both genders described associations
between the ε4 allele and higher TG and total and non-
HDL levels only in women. Additionally, Mendes-Lana
et al [38] showed that ε4 allele carriers present increased
risk for dyslipidemia when compared to ε2 allele car-
riers. However, De França et al [39] failed to demon-
strate an association between the ε4 allele with
increased TC and LDL-C values in healthy children,
suggesting that at least part of the described effect is
age-dependent. In fact, although a large number of stu-
dies show associations between APOE polymorphisms
with cardiovascular risk and lipid profile phenotypes in
different populations [40,41], some studies failed to
demonstrate this association [42,43].
Some functional studies may help in explaining our
findings. Miettinen et al [44] found a significant higher
cholesterol absorption in subjects with ε3a n dε4 alleles
compared with those carrying the ε2 allele after a nor-
mal diet. In addition, Weintraub et al [45] showed that
the slower hepatic clearance of dietary fat in ε2/3 sub-
jects could result in up-regulation of LDL receptors and
a subsequent decrease in plasma LDL-C levels.
Arterial stiffness and hypertension are the most
important risk factors for cardiovascular diseases [2,46].
Several studies have demonstrated association of these
with the metabolic profile [47,48]. The present study
failed to demonstrate an association between APOE
polymorphisms with blood pressure phenotypes and
arterial stiffness. Corroborating some results of this
study, Fuzikawa et al [49]studied 1406 Brazilian elderly
individuals and found no association between APOE
genotype and hypertension. Similarly, Carmo-Martins et
al [50] studied 672 Portuguese subjects and failed to
demonstrated an association with blood pressure.
Focusing on the arterial stiffness, studies [51] have
showed that the unfavorable lipid profile is associated
with lower arterial complacence due to reduced NO
bioavailability induced by dyslipidemia. Thus, we
expected ε4 allele carriers of the APOE polymorphism
would have a higher arterial stiffness when compared to
ε2 allele carriers. However, this was not evident in this
study, perhaps due to the little difference in mean lipid
fractions between the groups as well as the relative
young age of studied individuals. Studies involving the
APOE polymorphism with arterial stiffness phenotype
remain scarce in the literature. Thereby, further studies
involving the APOE polymorphism with arterial stiffness
phenotype are needed to clarify these issues.
Classically, obesity and hyperuricemia have shown to
have important roles in the development of cardiometa-
bolic disease [3,52,53]. This study showed that ε4 allele
is associated with higher uric acid levels when compared
to ε2 allele carriers. In addition, the presence of the ε4
allele offered increased risk for obesity and hyperurice-
mia. Unlike our findings, Liberopoulos et al [54] study-
ing healthy individuals showed that the ε4 allele was
associated with lower uric acid levels when compared to
allele ε2. Similar to our study, ε2 allele was associated
with lower serum levels of TC. Among the mechanisms
that may explain the higher prevalence of hyperuricemia
in individuals carrying the ε4 allele of APOE polymorph-
ism in our study could be the hyperinsulinemia
Alvim et al. Lipids in Health and Disease 2010, 9:128
http://www.lipidworld.com/content/9/1/128
Page 5 of 7associated with an unfavorable lipid profile. Several stu-
dies [55] have confirmed that under-excretion of uric
acid into the urine caused by the effect of insulin on the
urinary tubular tract has been demonstrated with phy-
siological hyperinsulinemia acutely reducing urinary uric
acid which could lead to a higher concentration of this
protein in the bloodstream. Due to the controversial
results and few existing data, studies of the association
between APOE polymorphism and uric acid need to be
further conducted. Similarly, studies associating obesity
phenotypes with APOE polymorphism have shown con-
troversial results. Corroborating our results, Carmo-
Martins et al. [50] showed that obese subjects (BMI ≥
30 Kg/m
2) are more prevalent in the ε4a l l e l eg r o u p
than in the ε2 allele group. In another study, Kolovou et
al [56] showed in coronary heart disease patients that
the prevalence of obese individuals was higher in the ε4
allele than in the ε2 allele group. Nevertheless, other
studies failed to show this association [57]. The relation-
ship between dyslipidemia and obesity is well established
in the literature. However, the mechanism by which
apolipoprotein E would influence obesity is not clear.
Karagiannides et al [58] showed through an experimen-
tal study that rat ApoE3
knock in after a high-fat diet
gained more weight than animals that did not express
the APOE protein and animals that expressed isoform
APOE2. Considering that in vitro receptor binding stu-
dies established that lipid-bound ApoE3 and ApoE4
have a similar affinity for LDLr, whereas lipid-bound
ApoE2 has a much lower affinity [59], we hypothesize
that this higher affinity of APOE4 isoform could result
in increased lipid deposition in the adipose tissue.
Our study has potential limitations. First, it should be
noted that the relative young age of the studied popula-
tion may preclude the identification of the association
between the studied genotype and measures of arterial
stiffness. Second, we did not evaluate the use of choles-
terol-lowering drugs, which could confound the
observed associations. Finally, if we have measured insu-
lin and urinary uric acid levels in this population, we
could shed light into the proposed mechanism for the
association of APOE polymorphism and serum uric acid.
In conclusion, the present study confirms the close
association between APOE polymorphism and the lipid
profile in individuals from the general population, but
failed to show this genetic risk factor as an important
modulator of arterial distensibility in this same sample.
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